JLE

Epileptic Disorders

MENU

Exceptional response to brivaracetam in a patient with refractory idiopathic generalized epilepsy and absence seizures Volume 20, numéro 1, February 2018

  • [Kalviainen et al., 2016] Kalviainen R., Genton P., Andermann E. Brivaracetam in Unverricht-Lundborg disease (EPM1): results from two randomized, double-blind, placebo-controlled studies. Epilepsia. 2016;57:210-221.
  • [Kasteleijn-Nolst Trenite et al., 2007] Kasteleijn-Nolst Trenite D.G., Genton P., Parain D. Evaluation of brivaracetam, a novel SV2A ligand, in the photosensitivity model. Neurology. 2007;69:1027-1034.
  • [Kwan et al., 2014] Kwan P., Trinka E., Van Paesschen W., Rektor I., Johnson M.E., Lu S. Adjunctive brivaracetam for uncontrolled focal and generalized epilepsies: results of a phase III, double-blind, randomized, placebo-controlled, flexible-dose trial. Epilepsia. 2014;55:38-46.
  • [Matagne et al., 2008] Matagne A., Margineanu D.G., Kenda B., Michel P., Klitgaard H. Anti-convulsive and anti-epileptic properties of brivaracetam (ucb 34714), a high-affinity ligand for the synaptic vesicle protein, SV2A. Br J Pharmacol. 2008;154:1662-1671.
  • [Steinig et al., 2017] Steinig I., von Podewils F., Moddel G. Postmarketing experience with brivaracetam in the treatment of epilepsies: a multicenter cohort study from Germany. Epilepsia. 2017;58:1208-1216.
  • [Xu and Bajjalieh, 2001] Xu T., Bajjalieh S.M. SV2 modulates the size of the readily releasable pool of secretory vesicles. Nat Cell Biol. 2001;3:691-698.